- The National Comprehensive Cancer Network (NCCN) updates colorectal cancer screening guidelines to include Guardant Health's Shield blood test.
- Shield is recognized for its efficacy in detecting colorectal cancer with a sensitivity of 83% according to the landmark ECLIPSE study.
- FDA-approved for adults aged 45 or older, the Shield test offers a non-invasive, blood-based screening option.
Guardant Health, Inc. (GH, Financial), a leader in precision oncology, has announced the inclusion of its Shield blood test in the updated colorectal cancer (CRC) screening guidelines by the National Comprehensive Cancer Network (NCCN). This milestone marks the first national guideline recommendation for Shield, enhancing patient access to this innovative screening method.
The Shield test is designed to detect colorectal cancer signals in the bloodstream through circulating tumor DNA (ctDNA). The updated NCCN guidelines now suggest that individuals aged 45 or older, at average risk, undergo Shield testing once every three years. This development is based on the results of the ECLIPSE study, a landmark research effort published in the New England Journal of Medicine, that highlights the test's 83% sensitivity in detecting colorectal cancer when compared to traditional colonoscopy screenings.
According to AmirAli Talasaz, Guardant Health's co-CEO, "With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of eligible Americans who are forgoing their recommended screening for colorectal cancer." The Shield test offers a non-invasive alternative, allowing its completion during any healthcare visit and is especially beneficial for those who prefer to avoid more invasive procedures.
Guardant Health (GH, Financial), committed to transforming cancer care, continues to pave the way with its advanced diagnostics, providing critical insights into cancer progression and treatment response. More information about Guardant Health's initiatives and tests can be found on their official website and social media platforms.
